作者
Jamil S Syed, Kevin A Nguyen, Theodore R Holford, Jonathan N Hofmann, Brian Shuch
发表日期
2019/1/15
期刊
Cancer
卷号
125
期号
2
页码范围
232-238
简介
Background
Patients treated for renal cell carcinoma (RCC) may be diagnosed with a metachronous, contralateral tumor. We evaluated the risks of contralateral tumor development using the Surveillance, Epidemiology, and End Results database.
Methods
Among RCC patients, we identified those with a metachronous, contralateral RCC diagnosed ≥1 year after primary diagnosis. We performed a competing risks analysis to evaluate associations between clinicopathologic factors and metachronous, bilateral RCC. Cumulative incidence and standardized incidence ratios (SIRs) were calculated.
Results
There were 80,403 cases of RCC identified, with a median follow‐up of 8.3 years; of these, 1063 (1.3%) developed metachronous, contralateral RCC (median of 6 years after diagnosis). The cumulative incidence at 10, 20, and 30 years of follow‐up was 1.5%, 3.1%, and 4.7%, respectively. An increased risk was …
学术搜索中的文章
JS Syed, KA Nguyen, TR Holford, JN Hofmann… - Cancer, 2019